Medical Advocates
HCV Infection/Disease
 
Drugs
 General Reports
Amantadine
Boceprevir
 Cyclosporine
Etanercept
 Erythropoietin
Corticosteroids
 Gammaglobulin
 Immunoglobulin
Interferons
 Lopinavir
 Meloxicam
Metformin
Nevirapine
Peg Interferon-Alfa-2a 
Peg Interferon-Alfa-2b  
Raltegravir
 Ribavirin
Rifampin
Rituximab
Statins
Tacrolimus
Telaprevir
Thalidomide
Valproic Acid
 Alternative Therapies		 Investigational Therapies
Post-Transplant Drugs






 
HCV Main Page Main New/Newsworthy    Home Page    
Last Update:  January 22, 2012
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
 

     Journal Papers, Abstracts, and Commentaries

 
Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow.
Asselah T, Marcellin P.
Liver Int.2012 Feb;32 Suppl 1:88-102. .
 Abstract
 
Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important?
Halfon P, Sarrazin C.
 Liver Int. 2012 Feb;32 Suppl 1:79-87. .
 Abstract

New targets for antiviral therapy of chronic hepatitis C.
Bühler S, Bartenschlager R.
 Liver Int. 2012 Feb;32 Suppl 1:9-16.
Abstract

FULL-TEXT ARTICLE
 The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors.
Kwo PY, Vinayek R.
 Gut Liver. 2011 Dec;5(4):406-17
 Paper

Provisional Guidance on the Use of Hepatitis C Virus Protease Inhibitors for Treatment of Hepatitis C
in HIV-Infected Persons.
Thomas DL, Bartlett JG, Peters MG, et al
Clin Infect Dis. 2011 Dec 14
 Abstract

Recent advance in antiviral drugs for hepatitis C.
Liu J, Shi S, Zhuang H, Luo G.
 Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2011 Nov;36(11):1025-36.
 Abstract

Mechanisms Involved in the Development of Chronic Hepatitis C as Potential Targets of Antiviral Therapy.
Jackowiak P, Figlerowicz M, Kurzyńska-Kokorniak A, Figlerowicz M.
Curr Pharm Biotechnol. 2011 Sep 9.
 Abstract

Oral combination therapy: Future hepatitis C virus treatment?
Hézode C.
J Hepatol. 2011 May
Abstract

Current drug discovery strategies for treatment of hepatitis C virus infection.
Cheng KC, Gupta S, Wang H,  et al
J Pharm Pharmacol. 2011 Jul;63(7):883-92.
 Abstract

Antiviral therapy: why does it fail in HCV-related chronic hepatitis?
Masarone M, Persico M.
 Expert Rev Anti Infect Ther. 2011 May;9(5):535-43..
 Abstract

Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection:
a cure and so much more.
 Pearlman BL, Traub N.
 Clin Infect Dis. 2011 Apr;52(7):889-900
 Abstract

Does the antiviral therapy of patients with chronic hepatitis exert nephrotoxic effects?
Gluhovschi C, Gadalean F, Kaycsa A, et al
 Immunopharmacol Immunotoxicol. 2011 Feb 14
 Abstract

Hepatitis C virus Resistance to Protease Inhibitors.
 Halfon P, Locarnini S.
J Hepatol. 2011 Jan 29.
 Abstract

Mixing the right hepatitis C inhibitor cocktail.
 Gelman MA, Glenn JS.
Trends Mol Med. 2010 Nov 22.
Abstract

Susceptibility of Treatment-Naive HCV Clinical Isolates to HCV Protease Inhibitors.
 Bae A, Sun SC, Qi X, et al
Antimicrob Agents Chemother. 2010 Sep 20
 Abstract

Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy:
a double-blind, placebo-controlled trial.
Morasco BJ, Loftis JM, Indest DW,  et  al
Psychosomatics. 2010 Sep;51(5):401-8.
 Abstract

Viral response to specifically targeted antiviral therapy for hepatitis C
and the implications for treatment success.
 Cooper C.
Can J Gastroenterol. 2010 Jun;24(6):385-90
 Abstract

New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.
 Seden K, Back D, Khoo S.
J Antimicrob Chemother. 2010 Mar 23
 Abstract

Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C
virus-related cirrhosis.
 Singal AK, Singh A, Jaganmohan  et al 
Clin Gastroenterol Hepatol. 2009 Oct 29
 Abstract

Compound Chinese herbal medicines, Chinese herbal drugs and their active extracts for treatment
of chronic hepatitis C: a systematic review and meta-analysis of randomized clinical trials
Qin XK, Han M, Liu JP.
Zhong Xi Yi Jie He Xue Bao. 2009 Oct;7(10):913-28.
 Abstract

Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C.
 Sroczynski G, Esteban E, Conrads-Frank A,, et a;
 J Viral Hepat. 2009 Jul 28.
 Abstract

New and experimental therapies for HCV.
 Pereira AA, Jacobson IM.
Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):403-11.
 Abstract

Decline in Male Sexual Desire, Function, and Satisfaction During and
After Antiviral Therapy for Chronic Hepatitis C.
 Dove LM, Rosen RC, Ramcharran D, et al
Gastroenterology. 2009 Jun 12.
Abstract

Antiviral resistance and specifically targeted therapy for HCV (STAT-C).
 Thompson AJ, McHutchison JG.
  J Viral Hepat. 2009 Jun;16(6):377-87
 Abstract

New drug targets for hepatitis C and other flaviviridae viruses.
 Paula T, Pablo R, Eugenia V, et al
 Infect Disord Drug Targets. 2009 Mar;9(2)
Abstract
 
Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy.
 Gaudieri S, Rauch A, Pfafferott K, et al
Hepatology. 2008 Dec 8
 Abstract
 
Antiviral therapy for recurrent liver graft infection with hepatitis C virus.
 Gurusamy KS, Osmani B, Xirouchakis E, et al
Cochrane Database Syst Rev. 2009 Jan 21;(1):CD006803.
 Abstract
 
New data and recommendations of antiviral therapy of chronic hepatitis B and C.
 Niederau C.
Internist (Berl). 2008 Mar 15
Abstract
 
Treatment regimens for patients with chronic hepatitis C.
 Trapero-Marugan M, González-Moreno L, Chaparro-Sánchez M, et al
Minerva Gastroenterol Dietol. 2008 Jun;54(2):209-17.
 Abstract
 
Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders:
an international, multicenter cohort study.
 Posthouwer D, Yee TT, Makris M, et al
 J Thromb Haemost. 2007 Aug;5(8):1624-1629.
 Abstract
 
Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in
Chronic Hepatitis C.
Lecube A, Hernández C, Simó R, et al
 Am J Gastroenterol. 2007 Jul 7;
 Abstract
 
Viral determinants of resistance to treatment in patients with hepatitis C
 Wohnsland A, Hofmann WP, Sarrazin C.   
Clin Microbiol Rev. 2007 Jan;20(1):23-38.
 Abstract
 
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
 Mehta SH, Lucas GM, Mirel LB, et al
AIDS. 2006 Nov 28;20(18):2361-9.
 Abstract
 
Antiviral therapy for hepatitis C virus-associated mixed cryoglobulinemia vasculitis:
A long-term follow-up study.
 Saadoun D, Resche-Rigon M, et al 
Arthritis Rheum. 2006 Oct 30;54(11):3696-3706
Abstract
 
Antiviral treatment of hepatitis C.
 Toniutto P, Fabris C, Pirisi M.
Expert Opin Pharmacother. 2006 Oct;7(15):2025-35.
 Abstract
 
Effectiveness of Antiviral Therapy in Patients with Chronic Hepatitis C Treated by Private
Practice Gastroenterologists.
Hofmann WP, Bock H, Weber C, et al
 Z Gastroenterol. 2006 Jan;44(1):25-31.
Abstract

The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based
approach.
 Camma C, Di Bona D, Craxi A. 
Curr Pharm Des. 2004;10(17):2123-30.
 Abstract
 
    Conference Reports, Abstracts, and Posters
 
 
POSTER
 Using the Substrate Envelope to Avoid Drug Resistance against HCV NS3/4A Protease Inhibitors
K Romano, A Ali, W Royer, C Schiffer
(18 CROI)
PDF Poster     Abstract

New Antiviral Therapies in the Management of HCV
S Zeuzem
(18th CROI)
 Abstract

POSTER
Influence of HAART on Hepatitis C Virus Escape from CD8+ T Cell Immune Pressure
J Rohrbach, M Tschochner, A Chopra, et al
(17th CROI)
PDF Poster     Abstract

The effect of nucleoside free HAART on the treatment of chronic HCV infection
M. Vogel, G. Ahlenstiel, G. Klausen, et al
 (5th IAS Conference)
 Abstract
Boceprevir
 

     Journal Papers, Abstracts, and Commentaries

 
Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C.
 Sarrazin C, Berg T, Cornberg M,  et al
 Z Gastroenterol. 2012 Jan;50(1):57-72.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
Shiffman ML, Esteban R.
 Liver Int. 2012 Feb;32 Suppl 1:54-60.
Abstract

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1
Manns MP, Markova AA, Serrano BC, Cornberg M.
 Liver Int. 2012 Feb;32 Suppl 1:27-31.
Abstract

Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors)
HCV Resistant Mutants among Treatment Naive Infected Individuals.
Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, et al
 J Clin Microbiol. 2011 Nov 23.
 Abstract

Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
Tungol A, Rademacher K, Schafer JA.
J Manag Care Pharm. 2011 Nov;17(9):685-94.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease
after treatment with telaprevir or boceprevir.
Susser S, Vermehren J, Forestier N, et al
 J Clin Virol. 2011 Sep 14.
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Boceprevir: A Protease Inhibitor for the Treatment of Chronic Hepatitis C (September).
Foote BC, Spooner LM, Belliveau PP.
 Ann Pharmacother. 2011 Aug 9
 Abstract

A sprint to increase response to HCV treatment: expectancies but caution.
Asselah T.
J Hepatol. 2011 Jun 30
 Abstract

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b
and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1):
an open-label, randomised, multicentre phase 2 trial.
 Kwo PY, Lawitz EJ, McCone J,. et al
 Lancet. 2010 Aug 28;376(9742):705-16
 Abstract

Highly sensitive determination of HCV protease inhibitors boceprevir (SCH 503034) and
telaprevir (VX 950) in human plasma by LC-MS/MS.
 Farnik H, El-Duweik J, Welsch C,
J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Dec 1;877(31):4001
 Abstract

    Conference Reports, Abstracts, and Posters

  POSTER
 Frequencies of Resistance-associated Amino Acid Variants following Combination
Treatment with BOC + P/R in Patients with Chronic HCV, Genotype-1
 R Barnard L Pedicone, E Chaudhri,  et al
 (18 CROI)
 PDF Poster     Abstract

HCV RESPOND-2 Final Results: High Sustained Virologic Response among Genotype-1
Previous Non-responders and Relapsers to pegIFN/RBV when Re-treated with BOC +
PEGINTRON/RBV
 S Gordon,  B Bacon, E Lawitz,  et al
 (18 CROI)
 Abstract

BOC Combined with P/R for Treatment-naïve Patients with HCV Genotype-1: SPRINT-2 Final Results
 M Sulkowski, F Poordad, J McCone, et al
 18 CROI)
 Abstract
Corticosteroids
 

     Journal Papers, Abstracts, and Commentaries

  Differential efficacy of corticosteroids and interferon in a patient with chronic hepatitis
C-autoimmune hepatitis overlap syndrome.
 Petersen-Benz C, Kasper HU, Dries V, Goeser T.
Clin Gastroenterol Hepatol. 2004 May;2(5):440-3
 Abstract
Cyclosporine
 
   Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation:
Effects on virus replication and recurrent hepatitis.
 Hilgard P, Kahraman A, Lehmann N, et al 
World J Gastroenterol. 2006 Feb 7;12(5):697-702.
 Paper
Erythropoietin
 
     Journal Papers, Abstracts, and Commentaries
 
 

Clinical recommendations for the use of recombinant human erythropoietin in patients with
hepatitis C virus being treated with ribavirin.
 Sherman M, Cohen L, Cooper MA, et al 
Can J Gastroenterol. 2006 Jul;20(7):479-85.
Abstract

Epoetin alfa for the Treatment of Combination Therapy-Induced Hemolytic Anemia in
Patients Infected with Hepatitis C Virus.
 Rivkin AM, Chawla S. 
Pharmacotherapy. 2005 Jun;25(6):862-7
 Abstract 

Normal erythropoietin response in chronic hepatitis C patients with ribavirin-induced anaemia.
Durante Mangoni E, Marrone A, Saviano D
Antivir Ther. 2003 Feb;8(1):57-63
 Abstract
Etanercept
 

     Journal Papers, Abstracts, and Commentaries

  Treatment with etanercept in six patients with chronic hepatitis C infection
and systemic autoimmune diseases.
Cavazzana I, Ceribelli A, Cattaneo R, Franceschini F.
Autoimmun Rev. 2008 Dec;8(2):104-6.
 Abstract
Gammaglobulin
 
     Journal Papers, Abstracts, and Commentaries
 
  Fibrosis regression induced by intravenous gammaglobulin treatment.
 Amital H, Rewald E, Levy Y, et al.
Ann Rheum Dis 2003 Feb;62(2):175-177
 Abstract
Immunoglobulin
 
      Journal Papers, Abstracts, and Commentaries
 
  Prophylaxis of Hepatitis C with Intramuscular Immunoglobulin: Clinical and Economic Appraisal.
 Piazza M, Sagliocca L, Tosone G, et al
BioDrugs. 1999 Oct;12(4):291-300.
 Abstract
Lopinavir
 
    Conference Reports, Abstracts, and Posters
 
  POSTER
 HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV coinfected patients starting anti-HCV treatment:
final results of a randomised, proof-of- principle clinical trial (KAMON 2 Study)
H. Hasson, L. Galli, G. Gallotta
(6th IAS Conference)
 Poster      Abstract
Meloxicam
 
     Journal Papers, Abstracts, and Commentaries
 
  Eight-week oral administration of meloxicam, a non-steroidal anti-inflammatory drug, prevents
dose reduction of pegylated interferon alpha-2a in the treatment of chronic hepatitis C.
 Kagawa T, Shiozawa H, Kojima SI, et al 
Hepatol Res. 2007 Sep 6;
 Abstract
Metformin
 
     Journal Papers, Abstracts, and Commentaries
 
  Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients
receiving peginterferon alfa-2a plus ribavirin.
 Romero-Gómez M, Diago M, Andrade RJ, et al 
Hepatology. 2009 Dec;50(6):1702-8.
 Abstract
Nevirapine
 
     Journal Papers, Abstracts, and Commentaries
 
  Analysis of Severe Hepatic Events Associated with Nevirapine-Containing Regimens :
CD4+ T-Cell Count and Gender in Hepatitis C Seropositive and Seronegative Patients.
 Torti C, Costarelli S, De Silvestri A, et al 
Drug Saf. 2007;30(12):1161-9.
 Abstract
Raltegravir
 
     Journal Papers, Abstracts, and Commentaries
 
  Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
Vispo E, Mena A, Maida I, et al
J Antimicrob Chemother. 2009 Dec 23
 Abstract
Rifampin
 

Rifampin/Pyrazinamide

     Journal Papers, Abstracts, and Commentaries

  Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy
requiring transplantation in an individual at low risk for hepatotoxicity.
 Kunimoto D, Warman A, Beckon A,  et al.
Clin Infect Dis. 2003 Jun 15;36(12):E158-61
 Abstract
Rituximab
 
   Journal Papers, Abstracts, and Commentaries
 
 
FULL-TEXT ARTICLE
 Rituximab treatment in hepatitis C infection: an in vitro model to study the impact of B cell depletion
on virus infectivity.
Stamataki Z, Tilakaratne S, Adams DH, McKeating JA.
PLoS One. 2011;6(9):e25789.
Paper

Rituximab plus Peg-Interferon {alpha} /ribavirin compared to Peg- Interferon
{alpha} /ribavirin in Hepatitis C related mixed cryoglobulinemia.
 Saadoun D, Resche Rigon M, et al
Blood. 2010 May
 Abstract

Efficacy and tolerability of rituximab with or without PEGylated interferon alfa-2b
plus ribavirin in severe hepatitis C virus-related vasculitis: A long-term followup
study of thirty-two patients.
 Terrier B, Saadoun D, Sène D, et al
Arthritis Rheum. 2009 Jul 30;60(8):2531-2540.
 Abstract

Hepatitis C virus infection and rituximab therapy after renal transplantation.
 Fabrizi F, Martin P, Elli A, et al 
Int J Artif Organs. 2007 May;30(5):445-9.
 Abstract
Statins
 
   Journal Papers, Abstracts, and Commentaries
 
  Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans.
 Henderson LM, Patel S, Giordano TP, et al 
Dig Dis Sci. 2009 Sep 3.
Abstract
Statins
 
   Journal Papers, Abstracts, and Commentaries
 
  Statin Therapy and Serum Transaminases Among a Cohort of HCV-Infected Veterans.
 Henderson LM, Patel S, Giordano TP, et al 
Dig Dis Sci. 2009 Sep 3.
Abstract
Tacrolimus
 
   Journal Papers, Abstracts, and Commentaries
 
  FULL-TEXT ARTICLE
Cyclosporine versus tacrolimus in patients with HCV infection after liver transplantation:
Effects on virus replication and recurrent hepatitis.
 Hilgard P, Kahraman A, Lehmann N, et al 
World J Gastroenterol. 2006 Feb 7;12(5):697-702.
 Paper
Telaprevir
 
  News
 
 

FDA Approves Telaprevir for HCV
USFDA May 23, 2011
 News Release

   Journal Papers, Abstracts, and Commentaries

 
Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C.
 Sarrazin C, Berg T, Cornberg M,  et al
 Z Gastroenterol. 2012 Jan;50(1):57-72.
Abstract
 
A WEEK-IN-REVIEW FEATURED REPORT
Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?
 Shiffman ML, Esteban R.
Liver Int. 2012 Feb;32 Suppl 1:54-60.
Abstract

Telaprevir user's guide.
 Liapakis AM, Jacobson I.
 Liver Int. 2012 Feb;32 Suppl 1:17-25
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Telaprevir for the treatment of chronic hepatitis C infection.
 Muir AJ.
Expert Rev Anti Infect Ther. 2011 Dec;9(12):1105-14.
 Abstract

Specific Detection of Naturally Occurring Telaprevir and Boceprevir (Protease Inhibitors)
HCV Resistant Mutants among Treatment Naive Infected Individuals.
 Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, et al
 J Clin Microbiol. 2011 Nov 23.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Discovery and development of telaprevir: an NS3-4A protease inhibitor for treating genotype 1 chronic hepatitis C virus
 Kwong AD, Kauffman RS, Hurter P, Mueller P.
Nat Biotechnol. 2011 Nov 8;29(11):993-1003.
Abstract

The Pharmacokinetic Interaction Between an Oral Contraceptive Containing Ethinyl Estradiol
and Norethindrone and the HCV Protease Inhibitor Telaprevir.
 Garg V, van Heeswijk R, Yang Y,  et al
 J Clin Pharmacol. 2011 Oct 30.
Abstract

Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.
 Tungol A, Rademacher K, Schafer JA.
J Manag Care Pharm. 2011 Nov;17(9):685-94.
 Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior
treatment response.
 Muir AJ, Poordad FF, McHutchison JG, et al
H epatology. 2011 Nov;54(5):1538-46.
 Abstract

Telaprevir for Chronic Hepatitis C with Genotype 1: A Meta-Analysis.
 Dang SS, Wang WJ, Wang XF,
Hepatogastroenterology. 2011 Aug 10;59(114).
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease
after treatment with telaprevir or boceprevir.
 Susser S, Vermehren J, Forestier N, et al
J Clin Virol. 2011 Sep 14.
Abstract

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with
HCV of genotype 1 in Japan.
 Kumada H, Toyota J, Okanoue T,  et al
 J Hepatol. 2011 Aug 6
 Abstract

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir
 (VX-950) and danoprevir (ITMN-191).
 Imhof I, Simmonds P.
 Hepatology. 2011 Apr;53(4):1090-9
 Abstract

Second phase HCV RNA decline during telaprevir based therapy increases with drug effectiveness:
Implications for treatment duration.
 Guedj J, Perelson AS.
 Hepatology. 2011 Mar 7.
Abstract

The efficacy and safety of telaprevir - a new protease inhibitor against hepatitis C virus.
 Gentile I, Carleo MA, Borgia F, et al
Expert Opin Investig Drugs. 2010 Jan;19(1):151-9.
 Abstract
 
Characterization of resistance to the protease inhibitor boceprevir in hepatitis C
virus-infected patients.
 Susser S, Welsch C, Wang Y, et al
Hepatology. 2009 Dec;50(6):1709-18.
 Abstract

 Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment
with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.
 Suzuki F, Akuta N, Suzuki Y, et al
Hepatol Res. 2009 Nov;39(11):1056-63
 Abstract
 
Sustained virological response in a patient with chronic hepatitis C treated by monotherapy
with the NS3-4A protease inhibitor telaprevir.
Suzuki F, Suzuki Y, Akuta N, et al
Clin Virol. 2009 Oct 24.
 Abstract
 

Telaprevir: hope on the horizon, getting closer.
 Weisberg IS, Jacobson IM.
Clin Liver Dis. 2009 Aug;13(3):441-52
 Abstract
 
FULL-TEXT ARTICLE
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
 Hézode C, Forestier N, Dusheiko G, et al
 N Engl J Med. 2009 Apr 30;360(18):1839-50
 Paper

Telaprevir for previously treated chronic HCV infection.
 McHutchison JG, Manns MP, Muir AJ, et al
N Engl J Med. 2010 Apr 8;362(14):1292-303.
 Abstract

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
 Hézode C, Forestier N, Dusheiko G, et al
 N Engl J Med. 2009 Apr 30;360(18):1839-50
 Abstract

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.
 McHutchison JG, Everson GT, Gordon SC, et al
 N Engl J Med. 2009 Apr 30;360(18):1827-38
 Abstract
 
Telaprevir: a promising protease inhibitor for the treatment of hepatitis C virus infection.
 Gentile I, Viola C, Borgia F, Castaldo G, Borgia G.
 Curr Med Chem. 2009;16(9):1115-21.
 AbstractT
 
    Conference Reports, Abstracts, and Posters
 
  POSTER
 Low-dose RTV and the Pharmacokinetics of the Investigational HCV Protease Inhibitor TVR in Healthy
Volunteers
V  Gar, X Luo, L McNair, et al
 (18 CROI)
PDF Poster     Abstract

Pharmacokinetic Interactions between ARV Agents and the Investigational HCV Protease Inhibitor TVR in
Healthy Volunteers
 R van Heeswijk, A Vandevoorde, G Boogaerts, et al
 V  Gar, X Luo, L McNair, et al
 (18 CROI)
 Abstract
Thalidomide
 
   Journal Papers, Abstracts, and Commentaries
 
  Thalidomide in the treatment of chronic hepatitis C unresponsive to alfa-interferon and
ribavirin.
 Milazzo L, Biasin M, Gatti N, et l
 Am J Gastroenterol. 2006 Feb;101(2):399-402
 Abstract
Valproic Acid
 
     Journal Papers, Abstracts, and Commentaries
 
  The safety of valproic Acid use for patients with hepatitis C infection.
Felker BL, Sloan KL, Dominitz JA, Barnes RF.
Am J Psychiatry 2003 Jan;160(1):174-8
 Abstract
Alternate Therapies
 

     Journal Papers, Abstracts, and Commentaries

 
High prevalence of potentially hepatotoxic herbal supplement use in patients with
fulminant hepatic failure
Estes JD, Stolpman D, Olyaei A 
Arch Surg. 2003 Aug;138(8):852-8.
 Abstract

The use of alternative medicine in the treatment of hepatitis C.
 Bean P
Am Clin Lab 2002 May;21(4):19-21
 Abstract

  
HCV Main Page Main New/Newsworthy    Home Page    

HCV Drugs

.